Back to Results
First PageMeta Content
Immunology / Autoinflammatory syndromes / Rheumatology / Rare diseases / Monoclonal antibodies / Canakinumab / Muckle–Wells syndrome / Cryopyrin-associated periodic syndrome / Familial cold urticaria / Health / Medicine / Immunosuppressants


PRIOR AUTHORIZATION POLICY Ilaris® (canakinumab for subcutaneous [SC] injection Novartis) To initiate a Coverage Review, Call[removed]
Add to Reading List

Document Date: 2013-11-01 14:13:13

Open Document

File Size: 105,36 KB

Share Result on Facebook

City

Bethesda / Tarrytown / Hanover / /

Company

Regeneron Pharmaceuticals Inc / Novartis Pharmaceuticals Corporation / Saag KG / /

Country

United States / /

Event

FDA Phase / Person Communication and Meetings / /

Facility

American College / National Library of Medicine / /

IndustryTerm

treatment of CAPS including Familial Cold Autoinflammatory Syndrome / /

MedicalCondition

Muckle-Wells Syndrome / cryopyrin-associated periodic syndrome / arthritis / rheumatoid arthritis / diabetes / fever / gouty arthritis / inflammatory markers / gout / significant active systemic disease / fatigue / tumor necrosis factor / juvenile idiopathic arthritis / acute gouty arthritis / Systemic Autoinflammatory Diseases / less joint pain / active rheumatoid arthritis / systemic juvenile idiopathic arthritis / Familial Cold Autoinflammatory Syndrome / Cryopyrin-Associated Periodic Syndromes / Neurologic manifestations / syndrome / /

Organization

International Congress / FDA / American College of Rheumatology / /

Person

Care Res (Hoboken) / Ann Rheum / /

/

Position

prescribing physician / physician / /

Product

Humira / Orencia / Kineret / SC / Enbrel / SC injection / Remicade / allopurinol / Arcalyst / Ilaris / canakinumab / /

URL

http /

SocialTag